CD4 and Sjogren syndrome: In an animal model of Sjögren syndrom, verbascoside improved salivary flow, reduced autoantibody levels, and modulated the frequency and activity of T and B cell populations (decreased the frequency of effector CD4+IFN-γ+Th1, CD4+IL-17+Th17 and CD4+PD-1+ICOS+Tfh cells and enhanced the IL-10 producing capacity of splenic B regulatory cells and TLR4+CXCR4+plasma cells) [226].